Haemophilia A without inhibitors – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:12:38 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemophilia A without inhibitors – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months) https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-emicizumab-for-infants-with-hemophilia-a-ages-birth-to-12-months/ Wed, 29 Apr 2026 14:47:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-emicizumab-for-infants-with-hemophilia-a-ages-birth-to-12-months/ This clinical trial is focused on studying Hemophilia A, a genetic disorder that affects the blood’s ability to clot properly, leading to excessive bleeding. The treatment being tested is called Emicizumab, which is also known by its code names RO5534262 and ACE910. Emicizumab is administered as a solution for injection under the skin, known as subcutaneous use. The purpose of this study is to evaluate how effective and safe Emicizumab is for patients from birth to 12 months of age who have Hemophilia A without inhibitors, which are substances that can interfere with treatment.

Participants in the study will receive Emicizumab injections over a period of time, and researchers will monitor various aspects of their health. This includes checking how well the treatment works in preventing bleeding episodes, as well as observing any side effects or reactions to the medication. The study will also look at how the body processes Emicizumab, which is referred to as its pharmacokinetic profile, and how the drug affects the body, known as pharmacodynamics. Additionally, the study will assess the immune response to the treatment.

The trial is designed to gather comprehensive data on the number of bleeding events, joint health, and any adverse events that may occur. Researchers will use tools like the Hemophilia Joint Health Score and MRI to evaluate joint health over time. The study aims to provide valuable insights into the long-term effects and benefits of Emicizumab for young patients with Hemophilia A, contributing to better management of the condition.

]]> Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab https://clinicaltrials.eu/trial/study-on-health-activity-and-joint-outcomes-in-patients-aged-13-69-with-severe-or-moderate-hemophilia-a-using-emicizumab/ Wed, 29 Apr 2026 14:27:59 +0000 https://clinicaltrials.eu/trial/study-on-health-activity-and-joint-outcomes-in-patients-aged-13-69-with-severe-or-moderate-hemophilia-a-using-emicizumab/ This clinical trial is focused on studying the effects of a medication called Hemlibra (also known as emicizumab) in people with a condition known as Hemophilia A. Hemophilia A is a genetic disorder where the blood does not clot properly, leading to excessive bleeding. This study is specifically for individuals with severe or moderate forms of Hemophilia A who do not have inhibitors against a protein called FVIII, which is important for blood clotting.

The purpose of the study is to evaluate how emicizumab affects joint health, overall health, and physical activity in participants. Participants will receive emicizumab as a solution for injection under the skin. The study will observe changes in joint health, the number of bleeding episodes, and the quality of life over time. Participants will also use a wearable activity tracker to monitor physical activity levels throughout the study.

The study will last for a period of up to 36 months. During this time, researchers will collect information on joint health using various assessments, including imaging techniques like MRI. They will also gather data on the participants’ physical activity and any changes in their health-related quality of life. The study will help understand the benefits and any potential side effects of using emicizumab for managing Hemophilia A.

]]> Study on the Safety and Effectiveness of SerpinPC for Patients with Severe Hemophilia A or B https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ Wed, 29 Apr 2026 14:23:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ This clinical trial is focused on studying the effects of a treatment called SerpinPC for individuals with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. Hemophilia is a condition where the blood does not clot properly, leading to excessive bleeding. The treatment being tested, SerpinPC, is a solution for injection that contains a modified form of a protein called human alpha-1 proteinase inhibitor. This study aims to evaluate how effective and safe SerpinPC is when given as a regular preventive treatment through subcutaneous injection, which means it is injected under the skin.

The purpose of the study is to assess the efficacy and safety of SerpinPC in people with these types of hemophilia. Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how well the treatment works in reducing bleeding episodes. The study will also look at the overall health and quality of life of the participants while they are receiving the treatment.

Throughout the study, participants will be observed for any changes in their condition, and the number of bleeding episodes they experience will be recorded. The study will help determine if SerpinPC can be a beneficial treatment option for those living with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. The trial is designed to gather important information that could lead to improved care and management of these conditions in the future.

]]>